新闻
BIO-B
--
0.00%
--
简报 Bio-Rad 报告 2021 年第二季度财务业绩
reuters.com · 07/29 20:50
Bio-Rad,10x Genomics 解决基因组学专利战
Rivals Bio-Rad Laboratories Inc and 10x Genomics Inc have settled their multi-front battle over microfluidic genetic analysis technology, 10x announced Tuesday.
Reuters · 07/27 19:39
BRIEF-Bio-Rad And 10X Genomics Announce Settlement To Resolve Multiple Litigations
reuters.com · 07/27 16:32
Brief-10X Genomics Inc 表示与 Bio-Rad Laboratories, Inc 达成了一项全球和解和交叉许可协议
reuters.com · 07/27 11:44
BRIEF-10X Genomics Signs Global Patent Cross License Agreement With Bio-Rad
reuters.com · 07/27 10:36
Bio-Rad,哈佛解决与法国公司的DNA分析专利纠纷
Bio-Rad Laboratories has settled its patent infringement claims against French biotech company Stilla Technologies three days after the start of a trial in Boston federal court, according to a court filing.
Reuters · 07/08 21:26
Brief-Bio-Rad 宣布与 Seegene 合作开发分子诊断测试产品
reuters.com · 06/30 21:04
Fed Circ重申了ITC在10倍裁决中的裁决以及Bio-Rad的专利斗争
The U.S. Court of Appeals for the Federal Circuit affirmed an International Trade Commission ruling Friday that some genetic-analysis products imported by 10x Genomics Inc infringe rival Bio-Rad Laboratories Inc's patents.
Reuters · 05/28 22:29
联邦巡回法院确认Bio-Rad侵犯了竞争对手10x Genomics的专利
The U.S. Court of Appeals for the Federal Circuit on Thursday upheld a ruling by the International Trade Commission that the importation and sale of Bio-Rad Laboratories Inc genetic-analysis products infringes patents owned by rival 10x Genomics Inc.
Reuters · 04/29 22:25
Brief-Bio Rad Laboratories报告第一季度非GAAP每股收益为5.21美元
reuters.com · 04/29 20:46
Fitch Assigns First-Time IDR of 'BBB' to STERIS plc; Outlook Stable
reuters.com · 03/17 12:36
Fitch Rates Illumina's Senior Unsecured Notes 'BBB'
reuters.com · 03/16 13:09
Fitch Rates Illumina's First-Time IDR 'BBB'; Outlook Stable
reuters.com · 03/08 21:43
Fitch Rates Agilent's Senior Unsecured Notes 'BBB+'
reuters.com · 03/03 14:03
Fitch Upgrades Thermo Fisher's Long-Term IDR to 'BBB+'; Outlook Stable
reuters.com · 03/01 21:23
简述Bio-Rad报告2020年第四季度和全年财务业绩
reuters.com · 02/11 22:31
Brief-Bio Rad Laboratories表示已启动重组计划,以促进正在进行的计划以改善运营绩效
reuters.com · 02/04 11:24
Renalytix AI Looks For U.S. Public Capital In IPO Filing
Seeking Alpha - Article · 2020/06/29 20:54
New GERM ETF focuses on biotech for infectious diseases
Seeking Alpha - Article · 2020/06/18 14:13
IPO Update: Genetron Holdings Files Proposed IPO Terms
Seeking Alpha - Article · 2020/06/16 17:12
微牛提供丰富的实时BIO-B股票新闻,让你可以通过多个平台了解BIO-B股票行情最新动态,这些免费的Bio Rad实验室-B新闻可以帮助你做出明智投资。
BIO-B 简况
Bio-Rad Laboratories, Inc.是一家制造商和经销商。该公司生产和供应生命科学研究、医疗保健、分析化学以及用于分离化学和生物材料及识别、分析和净化其成分等其他市场的产品与系统。该公司通过两个业务部门运营:生命科学部门和临床诊断部门。生命科学部门开发、制造及销售6000种用于研究技术、生物制药生产过程和食品测试制度的试剂、仪器和实验室仪器。临床诊断部门为全球诊断市场设计、制造、销售和支持服务于临床试验的测试系统、信息系统、测试套件和专门的质量控制器。